Research programme: RNA interference-based respiratory disorder therapeutics - Alnylam

Drug Profile

Research programme: RNA interference-based respiratory disorder therapeutics - Alnylam

Alternative Names: siRNA targeting IKK-beta - Alnylam; siRNA targeting IKK2 - Alnylam

Latest Information Update: 14 May 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Imperial College of Science, Technology and Medicine; Justus Liebig University
  • Class Small interfering RNA
  • Mechanism of Action I-kappa B kinase inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pulmonary fibrosis; Respiratory tract disorders

Most Recent Events

  • 18 Oct 2013 Discontinued - Preclinical for Pulmonary fibrosis in Germany (Parenteral)
  • 18 Oct 2013 Discontinued - Preclinical for Respiratory tract disorders in Germany (Parenteral)
  • 06 May 2011 No development reported - Preclinical for Pulmonary fibrosis in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top